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ABSTRACT 
 
Background: The use of a natural sweet protein is important as an attractive alternative to sucrose 
in the human diet. Rigorous research has identified the use of the artificial sweetener that leads to 
various diseases, cancer and heart disease. Many functional studies are necessary for examining 
the structure and biological activity of natural sweeteners such as Brazzein and its receptor 
targeting. In this report, we produced a panel of monoclonal antibodies against the recombinant 
brazzein which can be used for functional studies.  
Methods: Hybridomas cell fusion technology was used for the production of monoclonal antibody. 
BALB/c mice were immunized twice with purified fusion proteins with Freund adjuvant. Next, 14 
days after the last injection, blood sample was collected from the eye and serum was separated 
and the antibody titer was detected by enzyme-linked immunosorbent assay (ELISA). The mouse 
with the highest antibody titers was selected. Seven days before fusion, the selected mouse was 
boosted with 50 µg antigen into the peritoneum to develop a robust immune response and then 
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spleen cells were isolated from the same animal for fusion to myeloma SP2/0 to generate 
hybridoma cells.  
Results: Hybridoma clones were screened by ELISA and their monoclonal antibodies were 
purified. Specificity and reactivity of the monoclonal antibodies were determined by western blot 
analysis. We produced a panel of monoclonal antibodies that were highly specific and reacted with 
Brazzein protein that was detected by western blot analysis. 
Conclusion: These monoclonal antibodies bind to the MBP (Maltose binding protein)-containing 
recombinant protein in western blotting, so this antibody can be a useful probe for tracing proteins 
in basic research and pharmaceutical applications.  
 
 
Keywords: Brazzein; fusion protein; monoclonal antibody. 
 
1. INTRODUCTION 
 
Both natural and artificial sweeteners have been 
proved to be extremely for the human diet.  
Artificial sweeteners and sugar intake play an 
important role in the prevalence of some disease 
such as obesity, diabetes and cardiovascular 
disease. Recently, there has been an increasing 
demand for low–calorie sweeteners and healthy 
natural. Several natural-sweet proteins have 
been identified and among them brazzein is a 
small natural protein.  Brazzein is a sweet-tasting 
protein originally isolated and purified from the 
fresh fruit of Pentadiplandra brazzeana, a 
climbing vine that grows in Cameroon and Zaire 
[1-2]. Natural brazzein which consists of a single 
chain [3], is the smallest of the sweet-tasting 
proteins described to date [4-5]. Two forms of 
brazzein have been isolated from the fruit [6].  
The major form, which has pyroglutamic acid at 
the N-terminal consists of 54 amino acid residues 
and the minor form, which is similar to the major 
form except for the absence of pyroglutamic acid 
has 53 amino acid residues [7]. Brazzein is 500 
times sweeter than sucrose on a weight basis 
and its sweetness is stable when exposed to 
elevated temperatures for a period of 4 h [8-9].  
The three-dimensional structure of brazzein     
has been determined by H-NMR spectroscopy 
[10-11]. Its structure consists of one short alpha 
helix and a three-strand beta sheet. The C- and 
N-terminal regions are involved in the sweetness 
of brazzein and identify a number of residues in 
brazzein which are important for interaction with 
the receptor [12]. It is rich in lysine but               
contains no methionine, threonine or tryptophan 
[13]. The sweet taste of brazzein can be      
detected by human, old world monkeys and   
apes by taste trials. Till now, two T1R2-T1R3 
receptor proteins are identified for 
responsiveness to sweet ligands [14-15]. Sweet 
proteins interact with the receptor and then 
induce the receptor activation and sensation of 
sweetness [16].  
Because of its small size, rigidity, stability and 
solubility in water, brazzein offers advantages 
over other sweet tasting peptides and proteins 
system for detailed studies [17-18]. In addition, it 
is an ideal candidate for a low-calorie sweetener 
because of its natural origin and favorable 
physical properties [19-20]. Identification of the 
sweet-taste receptor and investigation of the 
interaction between the sweet receptor and 
sweet compounds like brazzein will be essential 
for understanding the molecular basis of this 
sensory transduction pathway [21]. Although the 
original source and gene sequences described, 
there is much information about function, 
receptors, signaling pathway and specific cellular 
location remains still unclear. In this regard, 
specific antibodies are necessary to investigate 
the function of brazzein. An effective antibody 
against brazzein is not yet available. To 
understand structural and chemical properties 
responsible for brazzein, we engineered a 
synthetic gene to express the brazzein molecule  
in E. coli in our laboratory [22].  
 
In this work, eight stable monoclonal antibodies 
against fusion protein brazzein were generated 
and characterized by indirect ELISA and western 
blot. Thus the mAbs can be used as tools in 
different molecular techniques [23]. Knowledge 
of its fundamental properties can be use in basic 
research and pharmaceutical application. 
 
2. MATERIALS AND METHODS 
 
2.1 Plasmid Construction and Protein 
Purification 
 
PMAL-Brazzein vector was constructed as 
described previously in our work in Tehran 
medical university (we named MBP-Br). The 
efficient expression of MBP-Brazzein fusion 
protein was induced by 1 mM IPTG at 37°C in            
E. coli BL21 (DE3) for 2 h. The fusion proteins 
were purified from the bacterial lysate by          
one-step amylase resin purifications described 
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previously [22]. Protein determination was done 
by Bradford’s dye binding assay and identified by 
12% SDS-PAGE [24].  
 
2.2 Preparation of Mouse  
 
In this work, old female BALB/c mice (4-6 week) 
obtained from the Pasteur Institute of IRAN. The 
first step, one mouse did not receive any 
antigenic was selected as a negative control and 
one mouse received 50 µg diluted MBP was 
selected as a positive control. Then, four old 
female BALB/c mice (4-6 week) were immunized 
by injections intraperitoneally (i.p) with 50 µg 
purified fusion protein MBP-Br that was diluted in 
phosphate buffer saline (PBS) with an equal 
volume of complete freundʼs adjuvant (100 µL of 
a 1:1 emulsion of antigen in PBS: adjuvant) and 
20 days later, the same mice were boosted again 
with amount of antigen with incomplete adjuvant. 
Next, 14 days after the last injection, 70 µL of 
blood was collected from the eye and serum was 
separated and the antibody titer of the after 
injection was compared with the before injection 
from the same animal as a baseline control for 
antibody titers of the antiserum by ELISA (1:500, 
1:1000, 1:10000 dilution of sera). The mouse 
with the highest antibody titer was selected for 
fusion to myeloma cells. Seven days prior to cell 
fusion, the selected mouse with high titer (1/1000 
dilution of sera) was boosted by the i.p route with 
50 µg of fusion protein. Pre-immune serum was 
taken before immunization and one mouse 
without any antigen were as negative control.  All 
procedures performed in studies involving 
animals in accordance with the ethical standards. 
 
2.3 Measurement of Humoral Antibody 
Response  
 
Blood samples were collected by retro-orbital 
puncture from immunized mice 7 days after the 
final booster injection and sera were tested for 
the presence of antibody. Serum antibody titer 
was determined by ELISA. Purified recombinant 
protein was individually diluted to a concentration 
of 10 µg/ml in PBS and 100 µl of each 
recombinant protein was added to separate wells 
of micro titer ELISA plates (Nunc, Denmark). 
Control well was coated with mice generated 
high serum antibody titer and negative wells 
were coated with the same mice before injection 
of antigen. Coated plates were stored at room 
temperature, blocked for 1h and washed three 
times with 0.1% BSA in PBS, prior to incubation 
with sera samples. After adding 100 µl of diluted 
sample of sera (1:500, 1:1000, 1:10000) to each 
well, the plate was incubated for 1 h at room 
temperature and then washed three times with 
washing buffer. Secondary antibody horseradish 
peroxidase-labeled conjugates goat anti-mouse 
IgG (sigma, USA) was added at 1/4000 dilution 
for 1 h at room temperature.  Peroxidase activity 
was revealed by adding 100 µl to each well 
solution of 3, 3ˈ, 5, 5ˈ-tetra methyl benzidine 
(TMB) (Sigma, USA) for 20 min in a dark place.  
The color development reaction was stopped by 
adding 0.1 ml of 5 M sulfuric acid (H2SO4) and 
the color intensity was read in a micro titer plate 
ELISA reader at 450 nm. The ratio of the optical 
density of the negative control was considered as 
ratio value. Ratio values ≥3 were chosen as 
positive.  Statistical analysis was assessed using 
SPSS16.0 and Microsoft Excel. 
 
2.4 Monoclonal Antibody Production 
 
SP2/0 myeloma cells (obtained from the Pasteur 
Institute of IRAN) were grown in RPMI 1640 
containing 10% fetal bovine serum (FBS) 
(Invitrogen, USA) at 37°C in a 5% CO 2 incubator 
one week prior to fusion. Then mouse was 
euthanized and spleen was removed.                
All surgical procedures were performed under 
sterile condition and anesthesia. The spleen cells 
were fused with the myeloma cell line at a ratio of 
3:1 via polyethylene glycol (PEG) (Sigma, USA) 
method, a material that causes the cell 
membrane to fuse.  The hybridoma cells were 
suspended in RPMI 1640 media (Invitrogen, 
USA) supplemented with hypoxantin-
aminopterin-thymidine medium (HAT) (Sigma, 
USA), 20% FBS and a feeder layer from un-
immunized mice that distributed to 96-well tissue 
culture plates and HAT medium were replaced 
every 2 or 3 days.  Subsequently, the micro titer 
plates were incubated at 37°C in a 5% CO 2 
incubator for two weeks. In HAT medium, only 
fused cells will grow. Then, clones were cultured 
in hypoxanthine thymidine (HT) (Sigma, USA) 
medium for a further two weeks. Hybridoma    
cell lines producing specific antibodies          
were subcloned by limiting dilution
 
to ensure the 
stability of the cell line and were passaged in 
every 2 or 3 days. Culture supernatants of                
the cloned cells were collected as the source              
of monoclonal antibodies. Supernatants from 
hybridomas were screened 12 days after fusion 
by ELISA. The positive clones were chosen and 
transferred to a tissue culture flask. Culture 
supernatants of SP2/0 myeloma cells before 
fusion were collected as a negative control. 
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2.5 Western Blotting 
 
The specificities of the mAbs were evaluated              
by western blot analysis. The MBP-Br fusion 
proteins were electrophoresed on 12% SDS-
PAGE (according to the Laemmli method) and 
transferred onto nitrocellulose membrane 
(Amersham Pharmacia, USA) by semi-dry 
blotting technique (Bio-RAD, USA) [25].  Non-
specific binding on the membranes was blocked 
in PBS-T (0.05% Tween 20 in PBS pH 7.3) for 1 
h at room temperature (16-24°C). The 
membranes were trimmed and cut into strips and 
strips were incubated with supernatants of 
hybridomas. After incubation, the strips were 
washed and incubated with 1:4000 dilution of 
horseradish peroxidase-labeled goat anti-mouse 
IgG (Sigma, USA) as a secondary antibody for 1 
h and washed three times. In the final step, strips 
were developed with diamino benzidine as a 
chromogenic substrate and hydrogen peroxidase 
(H2o2). The reaction was stopped by washing 
with water. In the control experiments, strips 
were incubated with immunized mice sera. 
Prestained protein markers were used for both 
SDS-PAGE and western blotting. 
 
2.6 Preparation and Purification of 
Monoclonal Antibodies 
 
In order to purify the antibody, we collected all of 
the supernatant culture and monoclonal 
antibodies were purified with protein G columns 
in PBS buffer (pH: 7.2) and antibody isotype 
determination were determined by the                
mouse monoclonal antibody isotyping kit (Sigma, 
USA). 
 
3. RESULTS 
 
BALB/c mice were immunized with MBP-Br 
fusion protein. Following three booster 
immunizations with the antigen, the titer of 
antibody in mice sera were determined using 
ELISA.  All mice have developed antibody titers 
(1/1000 dilution of sera), detectable even at a 
1:10000 dilution of the serum (Fig. 1). The 
mouse with the highest antibody titer was further 
boosted i.p and fusion was done to generate 
hybridomas. 
 
Using cell fusion method, for the first time we 
screened 38 antigen positive hybridomas and 
these positive clones were subcloned twice by 
limiting dilution (Table 1). Stable hybridomas cell 
lines were grown in 6-well plates. In HAT 
medium, only fused cells have grown and 
unfused myeloma cells after 10 days of fusion, 
were died in the presence of HAT medium. The 
qualitative and quantitative levels of the secreted 
antibody in the supernatant were screened by 
ELISA. Based on ELISA results, eight hybridoma 
cell lines producing specific mAbs against MBP-
Br were selected. These hybridomas were 
named D7, D9, G6, H4, H9, H11, F2 and F9 
respectively (Fig. 2). These positive clones were 
subcloned twice for one week by limiting dilution 
in a larger culture flask to obtain a large amount 
of antibody and their isotype was determined. 
About 50% of clones produced IgM and 50% 
produced the IgG1 subclass.  
 
The SDS-PAGE of MBP-Br fusion protein 
showed a prominent band at molecular weight of 
48.4 kDa. The proteins were transferred to the 
nitrocellulose membrane and the specificity and 
reactivity of the mAbs against MBP-Br proteins 
were determined by western blot analysis. 
Several primary clones and subclones were 
tested by western blotting to select the specific 
anti-MBP-Br monoclonal antibody. Western blot 
analysis showed that monoclonal antibodies D7, 
D9, G6, H4, H9, H11, F2 and F9 could react to 
MBP-Br but not reacted to MBP alone and the 
specificity of these antibodies were better than 
others. The anti-MBP-Br mAbs detected 48.4 
kDa polypeptide band (Fig. 3) and different 
concentrations of cell lysate were used in 
western blot analysis and all of them could detect 
approximately less than 1 ng of antigen in cell 
lysate. For checking competitive assay we 
incubated the D9 clone with 50 ug of the purified 
recombinant protein for 1 hour in suspension 
(liquid conditions) and were incubated with the 
membrane containing the purified recombinant 
protein and then the band was not seen that 
shows the specificity of antibody (Fig. 4). 
 
4. DISCUSSION 
 
Brazzein as a small sweet–tasting protein has 
mainly been studied in biochemical properties by 
Ming and Hellekant [6]. It is difficult to extract 
Brazzein protein from fresh fruit. Brazzein has 
been expressed in a wide of variety of vectors, 
but its expression is limited to host and tags 
types. There are no reports of successful 
development of monoclonal antibodies against 
Brazzein protein in any in-vitro system.  
Therefore, generation of Anti-brazzein antibody 
would help achieve a better understanding of its 
function.  The goal of this study was to generate 
and characterize monoclonal antibodies that 
highly specifically bind to brazzein protein. 
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Affinity tags can be defined as exogenous amino 
acid sequences with a high affinity for protein 
purification and detection. They can be helpful in 
stabilizing or enhancing their solubility. Sweet-
tasting brazzein has been used for the study of 
sweet taste receptors, signal transduction and for 
characterization of its biochemical properties              
[8-9].  
  
 
 
Fig. 1. Four female BALB/c mice were immunized with MBP-Br. Serum antibodies titer (diluted 
1:500, 1:1000 and 1:10000) measured by ELISA. Pre-immune serum was taken before 
immunization and one mouse without any antigenic were as negative control 
 
 
 
Fig. 2. Titers of stable cell line monoclonal antibodies in hybridoma clones measured by 
ELISA. Culture supernatants of SP2/0 myeloma cells before fusion were collected as a negative 
control 
 
Table 1. The presence of antibody in the supernatant of the 
Number Hybrid name OD (450
1 P1-A3 3.01
2 P1-A9 2.83
3 P1-B1 2.71
4 P1-B11 2.51
5 P1-B12 3.52
6 P1-E1 2.11
7 P1-F2 2.71
8 P1-F4 2.72
9 P1-G6 2.6 
10 P1-E2 2.1 
11 P1-H9 2.69
12 P2-A3 2.51
13 P2-A5 2.2 
14 P2-A7 0.7 
15 P2-A11 0.8 
16 P2-B9 0.7 
17 P2-F11 0.82
18 P2-H5 1.02
19 P2-H6 0.93
20 P2-H10 0.94
 
 
Fig. 3. Supernatant from hybridoma clones 
were screened by western blot against the 
recombinant protein MBP-Br. Lane 1  MBP 
negative control;  Lane 2, supernatant from 
hybridomas clone D7 react with MBP
Lane 3, supernatant from hybridomas clone 
D9 react with MBP-Br; Mr, Multicolor 
molecular protein markers
 
We first constructed the synthetic fragment 
encoding the amino acid sequence of brazzein 
by assembling two single strand oligonucleotides 
and subcloned them into the E. coli 
vector pMAL-C2X and pGEX-2T in our laboratory 
in previous work [22]. MBP is frequently used to 
attach a signal or carrier which can be used to 
deliver therapeutic or pharmaceutical proteins. 
We used MBP for the following featur
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hybridoma clones were tested 12 
days after fusion by ELISA 
 
 nm) Number Hybrid name OD (450
 21 P3-B4 1.23
 22 P3-D10 1.19
 23 P3-F2 0.95
 24 P3-G1 1.03
 25 P3-H4 1.34
 26 P3-G11 1.3
 27 P3-H2 1.23
 28 P4-G7 1.17
29 P4-H1 1.21
30 P4-H12 1.22
 31 P5-G5 1.33
 32 P6-D1 1.1
33 P6-D3 1.28
34 P6-D5 1.08
35 P6-D6 1.02
36 P6-D7 1.1
 37 P6-D9 1.25
 38 P6-H1 1.08
 39 Positive control 1.02
 40 Negative control 0.01
 
-Br; 
 
expression 
es: (a) one-
step adsorption purification; (b) a minimal effect 
on tertiary structure and biological activity; (c) 
detection and specific removal to produce the 
native protein; (d) simple and accurate assay of 
the recombinant protein during purification. Th
size of the MBP tag included one to some amino 
acids to complete proteins and in some cases 
consisted of several subunits that could be 
attached to either the C- or N-terminus of the 
protein. MBP tag was purified under its specific 
buffer conditions. For immunization, the actual 
timing may vary depending on the purity and 
nature of the purified antigen used for the 
immunization. In general, it is difficult to decide 
on the best fusion system for a specific protein of 
interest. This depends on qualities of
protein itself such as stability, hydrophobicity and 
the application of the protein because brazzein 
expression is very difficult on its own with a small 
molecular mass. To improve production level, the 
synthetic brazzein gene was cloned and in
into the expression vectors pMAL-
expression was obtained in E. coli
The expression of fusion proteins allowed for 
their convenient purification from other soluble 
bacterial proteins by amylase resin 
production of this recombinant was recognized
SDS-PAGE, which was then used as an 
immunogen to produce monoclonal antibodies. 
The high yield and solubility of maltose
proteins are also major effects of high
production [27].   
 
 
 
 
 
 
 
 nm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e 
 the target 
serted 
C2X. Brazzein 
 in high yields.  
[26]. The 
 in 
-binding 
-throughput 
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Fig. 4. Western blot analysis of D9 supernatant antibody against different concentration of 
MBP-Br antigen. MW, Multicolor molecular weight protein markers. Lane1-5, different 
concentrations of MBP-Br (0.5, 0.08, 0.01, 0.001, 0.0001 µg respectively). Lane 6, the D9 clone 
incubated with 50 ug of the purified recombinant protein for 1 hour in suspension (liquid 
conditions) and then incubated with the membrane containing the purified recombinant 
protein that band is abolished. Lane 7, MBP negative control
 
To generate monoclonal antibodies specific for 
MBP-Br, one of the several mice immunized with 
a protein containing MBP-Br that had higher titer 
was euthanized and spleen cells were used to 
fuse with SP2/0 myeloma cells. Usually, an adult 
animal was been used effectively in the 
generation of unique monoclonal antibodies. In 
the first step, BALB/C mice were immunized with 
70 µg pure antigens with complete Freund’s 
adjuvant by i.p injection, but all mice died due to 
the toxicity of pure antigen (this procedure was 
repeated three times). In the next step, antigen 
was diluted with PBS and then injected into mice 
with complete Freund’s adjuvant by i.p injection. 
BALB/c mice developed sufficient serum 
antibody titer when immunized with MBP-Br, in 
comparison with before antigen injection. In 
addition, previous experiment screening with 
MBP-Br coated on ELISA plates showed mice 
immunized with MBP-Br generated high serum 
antibody titer (the serum diluted 1/500, 1/1000, 
1/10000). Therefore, MBP is immunogenic and 
can often be used directly as an antigen in 
antibody production [27].   
 
As a result, eight hybridoma clones (from 38 
clones) secreted antibodies. Eight of these were 
high titer-antibody measured by ELISA and could 
be used to detect the Brazzein protein. Most 
supernatant hybridoma cells were titers higher 
than 1 at OD 450 nm and the others had 0.5-0.9 
at OD 450 nm by ELISA. Western blot analysis 
was used to detect the specificity of these 
antibodies to recombinant proteins. The reactivity 
was observed in western blot using monoclonal 
antibody against the fusion antigen. All mAb 
recognized only a band with apparent molecular 
weight of 48.4 kDa. The results show that all 
these monoclonal antibodies were highly specific 
for Brazzein partner of fusion protein and reacted 
with fusion antigen proteins. We used GST as 
control and observed that monoclonal antibodies 
could not detect GST proteins [22]. Different 
concentrations of cell lysates were used in 
western blot analysis. Fig. 4 shows that D9 mAb 
could detect approximately less than 1 ng of 48.4 
kDa antigen in a cell lysate. Berlec and 
colleagues produced polyclonal antibodies 
against brazzein protein fused to His-tag [28]. 
Specificity of monoclonal antibodies (recognize 
only specific epitope) are better than polyclonal 
antibody (recognize multiple epitopes) and 
expression of brazzein in MBP can elicit cellular 
and humoral immune responses. 
 
5. CONCLUSION 
 
The Brazzein protein is useful in research and 
can be purified and assayed by ELISA or any 
other immunochemical detection method. Many 
monoclonal antibodies have been utilized for 
therapeutic, pharmacy, industry and basic 
research [29-30]. In this study, we described how 
to generate a panel of monoclonal antibodies 
that highly bind to protein and can be utilized for 
a variety of purposes such as detection, 
immunoaffinity purification, specific interaction of 
sweet protein with taste receptor and research. 
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We recommend using the dual affinity tag to 
increase the purity and high yield; one tag can be 
used for purification and the other for detection, 
then the tag can be removed with a suitable 
enzyme.  In situ production in other bacteria or 
eukaryotic systems would provide a low-calorie 
sweet-tasting product. 
 
COMPETING INTERESTS 
 
Authors have declared that no competing 
interests exist. 
 
REFERENCES 
 
1. Assadi-Porter FM, et al. Brazzein, a small, 
sweet protein: Effects of mutations on             
its structure, dynamics and functional 
properties. Chem Senses. 2005;30Suppl 1: 
i90-1. 
2. Nagata K, et al. The structure of brazzein, 
a sweet-tasting protein from the wild 
African plant Pentadiplandra brazzeana. 
Acta Crystallogr D Biol Crystallogr. 2013; 
69(Pt 4):642-7. 
3. Dittli SM, et al. Structural role of the 
terminal disulfide bond in the sweetness of 
brazzein. Chem Senses. 2011;36(9):821-
30. 
4. Faus I. Recent developments in the 
characterization and biotechnological 
production of sweet-tasting proteins. Appl 
Microbiol Biotechnol. 2000;53(2):145-51. 
5. Masuda T, Kitabatake N. Developments             
in biotechnological production of sweet 
proteins. J Biosci Bioeng. 2006;102(5): 
375-89. 
6. Ming, D. and Hellekant, G., Brazzein, a 
new high-potency thermostable sweet 
protein from Pentadiplandra brazzeana B. 
FEBS Lett. 1994;355(1):106-8. 
7. Assadi-Porter FM, Aceti DJ, Markley JL. 
Sweetness determinant sites of brazzein, a 
small, heat-stable, sweet-tasting protein. 
Arch Biochem Biophys. 2000;376(2):259-
65. 
8. Hellekant G, Danilova V. Brazzein a small, 
sweet protein: Discovery and physiological 
overview. Chem Senses. 2005;30(Suppl1): 
88-9. 
9. Walters DE, Hellekant G. Interactions of 
the sweet protein brazzein with the sweet 
taste receptor. J Agric Food Chem. 2006; 
54(26):10129-33. 
10. Assadi-Porter FM, et al. Efficient 
production of recombinant brazzein, a 
small, heat-stable, sweet-tasting protein of 
plant origin. Arch Biochem Biophys. 2000; 
376(2):252-8. 
11. Zhao Q, et al. Probing the sweet 
determinants of brazzein: Wild-type 
brazzein and a tasteless variant, brazzein-
ins (R18a-I18b), exhibit different pH-
dependent NMR chemical shifts. 
Biochemical and Biophysical Research 
Communications. 2005;335(1):256-263. 
12. Kant R. Sweet proteins--potential 
replacement for artificial low calorie 
sweeteners. Nutr J. 2005;4:1-6. 
13. Jin Z, et al. Critical regions for the 
sweetness of brazzein. FEBS Lett. 2003; 
544(1-3):33-7. 
14. Temussi PA. Why are sweet proteins 
sweet? Interaction of brazzein, monellin 
and thaumatin with the T1R2-T1R3 
receptor. FEBS Lett. 2002;526(1-3):1-4. 
15. Jiang P, et al. Molecular mechanisms of 
sweet receptor function. Chem Senses. 
2005;30(Suppl1):i17-8. 
16. Singarapu KK, et al. Structure-function 
relationships of brazzein variants with 
altered interactions with the human sweet 
taste receptor. Protein Sci. 2016;25(3): 
711-9. 
17. Yan S, et al. Expression of plant sweet 
protein brazzein in the milk of transgenic 
mice. PLoS One. 2013;8(10):e76769. 
18. Jo HJ, Noh JS, Kong KH. Efficient 
secretory expression of the sweet-tasting 
protein brazzein in the yeast 
Kluyveromyces lactis. Protein Expr Purif. 
2013;90(2): 84-9.  
19. Assadi-Porter FM, Patry S, Markley JL. 
Efficient and rapid protein expression            
and purification of small high disulfide 
containing sweet protein brazzein in E. 
coli. Protein Expr Purif. 2008;58(2):263-8.  
20. Grembecka M. Natural sweeteners in a 
human diet. Rocz Panstw Zakl Hig. 2015; 
66(3):195-202.  
21. Morini G, Bassoli A, Temussi PA. From 
small sweeteners to sweet proteins: 
Anatomy of the binding sites of the human 
T1R2_T1R3 receptor. J Med Chem. 2005; 
48(17):5520-9.  
22. Mansouri F, Modarressi MH, Abolhassani 
M, Parivar K. Synthesis and production of 
sweet-tasting protein in E. coli and 
purification by amylose resin. Journal of 
Sciences, Islamic Republic of Iran. 2011; 
22(2):105-110.  
23. Chusainow J, et al. A study of monoclonal 
antibody-producing CHO cell lines: What 
  
 
 
Mansouri and Modarressi; BJI, 18(4): 1-9, 2017; Article no.BJI.33505 
 
 
 
9 
 
makes a stable high producer? Biotechnol 
Bioeng. 2009;102(4):1182-96.  
24. Bradford MM. A rapid and sensitive 
method for the quantitation of microgram 
quantities of protein utilizing the principle     
of protein-dye binding. Analytical 
Biochemistry. 1976;72(1):248-254.  
25. Laemmli UK. Cleavage of structural 
proteins during the assembly of the head 
of bacteriophage T4. Nature. 1970; 
227(5259):680-5.  
26. Hsu SC, et al. A monoclonal antibody 
reacts with maltose-binding protein of 
Escherichia coli and related enteric 
bacteria. J Immunol Methods. 1997; 
204(2):169-174.  
27. Terpe K. Overview of tag protein fusions: 
From molecular and biochemical 
fundamentals to commercial systems. Appl 
Microbiol Biotechnol. 2003;60(5):523-533.  
28. Berlec A, et al. Expression of the sweet-
tasting plant protein brazzein in 
Escherichia coli and Lactococcus lactis: A 
path toward sweet lactic acid bacteria. 
Appl Microbiol Biotechnol. 2006;73(1): 
158-65.  
29. Presta LG. Molecular engineering and 
design of therapeutic antibodies. Curr Opin 
Immunol. 2008;20(4):460-70. 
30. Pavlou AK, Belsey MJ. The therapeutic 
antibodies market to 2008. Eur J Pharm 
Biopharm. 2005;59(3):389-96. 
_________________________________________________________________________________ 
© 2017 Mansouri and Modarressi; This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
 
 
 
 
Peer-review history: 
The peer review history for this paper can be accessed here: 
http://sciencedomain.org/review-history/19687 
